Costs and impacts of vaccine preparedness investments for SARS-X pandemics
This paper demonstrates that strategic pre-pandemic investments in vaccine preparedness—particularly those accelerating vaccine availability, combining R&D with manufacturing capacity, and ensuring equitable global distribution—can significantly reduce the projected economic and human losses of future SARS-X outbreaks.